摘要
结外NK/T细胞淋巴瘤是中国最常见的非霍奇金淋巴瘤之一,其恶性程度高,侵袭性强,目前尚无国际标准治疗方案。本文报道了1例晚期结外NK/T细胞淋巴瘤患者在一线治疗中出现疾病进展后通过使用PD-1单抗联合化疗或联合表观遗传学药物治疗方案而获良好缓解,为自体造血干细胞移植创造了机会。这一治疗策略值得临床进一步探讨。
Extranodal NK/T-cell lymphoma is one of the most common non-Hodgkin lymphomas in China.It is highly malignant and aggressive,and there is currently no international standard treatment plan.This article reports a patient with advanced extranodal NK/T cell lymphoma who achieved good remission with PD-1 monoclonal antibody combined with chemotherapy or combined with epigenetic drugs after disease progression in first-line therapy,that creates an opportunity for autologous hematopoietic stem cell transplantation.This treatment strategy is worthy of further clinical investigation.
作者
左轶朗
李亚军
肖玲
曾若兰
贺怡子
陈晓艳
周辉
Zuo Yilang;Li Yajun;Xiao Ling;Zeng Ruolan;He Yizi;Chen Xiaoyan;Zhou Hui(Graduate Collaborative Training Base of Hunan Cancer Hospital,Hengyang Medical School,University of South China,Hengyang 421001,China;School of Basic Medicine,Central South University,Changsha 410013,China;Hunan Cancer Hospital/Affiliated Cancer Hospital of Xiangya School of Medicine,Central South University,Changsha 410013,China)
出处
《中华转移性肿瘤杂志》
2022年第1期63-65,共3页
Chinese Journal of Metastatic Cancer
基金
湖南省自然科学基金(2021JJ30425)
长沙市自然科学基金(kq2014206)
湖南省卫生健康委科研计划项目(20201659)
湖南省肿瘤医院"科研攀登计划"(ZX2020003)
十三五新药创制国家科技计划重大专项子课题(2020ZX09201-019)。
